Zacks Research Upgrades InflaRx (NASDAQ:IFRX) to Strong-Buy

InflaRx (NASDAQ:IFRX) was upgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

A number of other equities analysts have also recently issued reports on the company. Raymond James Financial upgraded InflaRx from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $7.00 to $9.00 in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Wall Street Zen upgraded shares of InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Oppenheimer started coverage on shares of InflaRx in a research note on Friday, April 24th. They issued an “outperform” rating and a $5.00 price objective on the stock. Finally, HC Wainwright lifted their price objective on shares of InflaRx from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, May 11th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.00.

InflaRx Stock Performance

IFRX stock opened at $1.69 on Monday. The stock’s 50 day simple moving average is $2.02 and its 200 day simple moving average is $1.49. The company has a market cap of $122.17 million, a P/E ratio of -2.38 and a beta of 2.44. InflaRx has a fifty-two week low of $0.74 and a fifty-two week high of $2.95.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. Equities analysts predict that InflaRx will post -0.29 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. 683 Capital Management LLC raised its stake in shares of InflaRx by 47.3% in the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after buying an additional 1,065,000 shares during the period. Eversept Partners LP lifted its stake in shares of InflaRx by 1.5% during the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock valued at $1,775,000 after buying an additional 26,677 shares in the last quarter. DCF Advisers LLC bought a new position in InflaRx in the 4th quarter worth approximately $160,000. Concurrent Investment Advisors LLC grew its stake in InflaRx by 56.9% in the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after buying an additional 19,200 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in InflaRx during the 3rd quarter valued at $3,316,000. 42.39% of the stock is owned by institutional investors.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.